RapiMed® is an innovative pharmaceutical and OTC oral delivery method utilizing “Quick Melt Technology”. RapiMed® oral tablets dissolve in 30 seconds or less, providing rapid delivery of medicine without water. RapiMed® technology can be applied to a wide variety of drugs, providing pharmaceutical and OTC companies the highly valuable opportunity for product line extension and diversification.
ScripsAmerica holds the exclusive rights to Rapimed and anticipates the launching of its first line of products in Q4 2013. The first RapiMed product to enter the market will be 80mg and 160mg Acetaminophen, which is the base formulation in Tylenol. This product will target children 2-11 years old and provide ease of administration as well as safe and effective dosage applications.
Upon the launch of RapiMed® and the establishment of national distribution outlets, ScripsAmerica intends to launch additional RapiMed® medicine and vitamin categories that will be marketed and distributed into the already established distribution down-line. These additional medicine and vitamin categories include:
